human
metapneumoviru
hmpv
recent
shown
promin
caus
respiratori
infect
immunocompromis
host
associ
high
morbid
mortal
report
case
hmpv
pneumonia
lung
transplant
recipi
present
respiratori
failur
sepsi
syndrom
hmpv
diagnos
polymeras
chain
reaction
treat
intraven
ribavirin
success
outcom
j
heart
lung
transplant
copyright
intern
societi
heart
lung
transplant
lung
transplant
recipi
increas
risk
respiratori
tract
infect
due
continu
exposur
allograft
environ
decreas
mucociliari
clearanc
lymphat
drainag
human
metapneumoviru
hmpv
coronaviru
isol
symptomat
lung
transplant
recipi
hmpv
recogn
caus
respiratori
failur
death
patient
hematolog
malign
recipi
bone
marrow
solidorgan
transplant
report
case
hmpv
pneumonia
lung
transplant
recipi
diagnos
polymeras
chain
reaction
pcr
success
treat
intraven
ribavirin
white
woman
underw
doublelung
transplant
septemb
chronic
obstruct
pulmonari
diseas
receiv
mg
alemtuzumab
monoclon
antibodi
mg
methylprednisolon
induct
therapi
time
transplant
postop
cours
unev
discharg
day
transplant
immunosuppress
regimen
discharg
includ
oral
tacrolimu
target
level
ngml
mgday
oral
prednison
also
prescrib
oral
voriconazol
mg
twice
daili
oral
valganciclovir
mg
daili
trimethoprimsulfamethoxazol
singl
strength
time
week
aspergillu
cytomegaloviru
pneumocysti
jirovecii
prophylaxi
respect
patient
well
clinic
surveil
bronchoscopi
neg
acut
cellular
reject
six
month
transplant
april
present
histori
wateri
diarrhea
abdomin
pain
also
note
mild
upper
respiratori
infect
uri
symptom
similar
husband
selflimit
ill
preced
week
workup
clostridium
difficil
cytomegaloviru
neg
start
steroid
possibl
relaps
crohn
diseas
accord
gastroenterolog
recommend
result
symptomat
improv
abdomin
symptom
continu
upper
respiratori
symptom
persist
respiratori
symptom
prompt
bronchoscopi
biopsi
procedur
develop
fever
hypotens
respiratori
distress
requir
endotrach
intub
mechan
ventil
pressor
support
norepinephrin
vasopressin
also
start
empir
antibiot
coverag
intraven
cefepim
vancomycin
metronidazol
possibl
septic
shock
meanwhil
earlier
transbronchi
biopsi
reveal
reject
concomit
bronchoalveolar
lavag
cultur
grew
light
betalactamaseneg
haemophilu
influenza
rare
aspergillu
niger
viral
shell
assay
neg
adenoviru
respiratori
syncyti
viru
influenza
viru
parainfluenza
viru
continu
requir
pressor
support
increas
oxygen
requir
chest
radiograph
reveal
diffus
bilater
infiltr
owe
worsen
clinic
condit
hmpv
pcr
request
nasopharyng
swab
previous
store
bronchoalveolar
lavag
realtim
pcr
hmpv
perform
report
previous
sampl
posit
patient
subsequ
start
inhal
ribavirin
continu
shock
develop
acut
respiratori
distress
syndrom
start
venoven
extracorpor
membran
oxygen
ecmo
switch
inhal
intraven
iv
ribavirin
day
given
load
dose
mgkg
iv
day
day
receiv
mgkg
iv
daili
later
continu
mgkg
iv
daili
treat
iv
ribavirin
hmpv
pcr
bronchoalveolar
lavag
becam
neg
day
iv
ribavirin
therapi
show
mark
clinic
improv
taken
ecmo
pressor
ventilatori
support
day
initi
iv
ribavirin
therapi
figur
patient
discharg
day
respiratori
failur
rehabilit
facil
continu
well
repeat
biopsi
month
complet
iv
ribavirin
show
evid
pneumonia
reject
cours
therapi
ribavirin
transient
low
white
cell
count
anemia
recov
complet
complet
treatment
repeat
hmpv
pcr
assess
done
start
month
treatment
remain
neg
human
metapneumoviru
hmpv
recent
discov
communityacquir
season
respiratori
pathogen
although
viru
initi
detect
respiratori
sampl
netherland
retrospect
analys
store
sampl
implic
caus
pulmonari
diseas
human
last
year
europ
north
america
report
first
case
hmpv
pneumonia
lung
transplant
recipi
success
outcom
associ
iv
ribavirin
therapi
hmpv
negativesens
nonseg
rna
paramyxoviru
share
season
variat
respiratori
syncyti
viru
case
diagnos
late
winter
earli
spring
hmpv
caus
symptomat
asymptomat
upper
lower
respiratori
tract
diseas
although
lower
respiratori
tract
diseas
like
extrem
age
clinic
featur
hmpv
infect
present
usual
upper
respiratori
tract
infect
progress
respiratori
failur
requir
mechan
ventil
cultureneg
sepsi
syndrom
pulmonari
hemorrhag
possibl
due
increas
cytokin
product
specif
interferonalpha
persist
asymptomat
presenc
hmpv
respiratori
tract
demonstr
stem
cell
transplant
recipi
although
signific
longterm
outcom
yet
determin
lung
transplant
recipi
data
hmpv
infect
current
limit
hmpv
shown
present
symptomat
asymptomat
recipi
role
acut
complic
acut
allograft
reject
longterm
outcom
bronchiol
obliteran
syndrom
inconclus
investig
moreov
success
system
antivir
regimen
sever
lower
respiratori
tract
diseas
determin
ribavirin
synthet
guanosin
nucleosid
analog
act
inhibit
viral
rna
polymeras
use
success
respiratori
syncyti
viru
infect
lung
transplant
recipi
signific
vitro
activ
hmpv
anim
model
shown
decreas
hmpv
replic
inflamm
lung
data
immunocompromis
host
regard
treatment
hmpv
ribavirin
limit
use
inhal
ribavirin
success
realtim
pcr
use
wide
reliabl
detect
hmpv
compar
evalu
amplif
n
gene
use
realtim
pcr
found
particularli
suitabl
diagnosi
hmpv
case
patient
may
acquir
hmpv
infect
contact
husband
uri
symptom
preced
week
husband
recov
develop
sever
respiratori
ill
perhap
due
immunocompromis
statu
introduct
hmpv
lower
respiratori
tract
result
bronchoscopi
transbronchi
biopsi
procedur
altern
acut
worsen
respiratori
symptom
bronchoscopi
may
attribut
presenc
h
influenza
bronchoalveolar
lavag
patient
howev
seem
unlik
sever
reason
first
h
influenza
usual
colon
respiratori
tract
patient
chronic
lung
diseas
isol
organ
alway
associ
activ
diseas
second
clinic
present
septic
shock
usual
seen
younger
patient
splenectomi
function
asplenia
patient
h
influenza
septic
shock
system
bacteri
infect
typic
exhibit
leukocytosi
bandemia
posit
blood
cultur
aforement
risk
factor
featur
absent
patient
third
isol
betalactamaseneg
sensit
cefepim
patient
report
continu
deterior
clinic
despit
appropri
antibiot
coverag
improv
occur
initi
system
antivir
agent
similarli
detect
hmpv
bronchial
secret
may
suggest
colon
howev
believ
less
like
patient
develop
respiratori
syndrom
typic
cultureneg
sepsi
syndrom
improv
administr
ribavirin
initi
worsen
respiratori
symptom
inhal
ribavirin
due
develop
bronchospasm
usual
note
rout
evidenc
increas
peak
airway
pressur
patient
start
ribavirin
owe
potenti
activ
hmpv
use
intraven
ribavirin
clearli
associ
improv
subsequ
recoveri
patient
although
welldefin
studi
requir
determin
incid
hmpv
transplant
recipi
acut
respiratori
ill
establish
optim
treatment
hmpv
lung
transplant
recipi
case
suggest
use
intraven
ribavirin
option
case
hmpv
pneumonia
immunocompromis
host
